Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Imiquimod 3.75% · 1 trial · 1 indication
The number of participants with reduction in number of AKs on the face and/or scalp after application of imiquimod 3.75%.
| Arm | Type | Description |
|---|---|---|
| Imiquimod 3.75% cream | EXPERIMENTAL | applied topically |
| Name | Type | Description |
|---|---|---|
| Imiquimod 3.75% Cream | DRUG | Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14). |
Inclusion Criteria: * Adults at least 18 years old. * Subjects must be in good general health as confirmed by the medical history. * Subjects must be able to read, sign, and understand the informed consent. * Prior to imiquimod therapy, subjects must have at least 4-8 actinic keratoses on the face ...